Xevant launches GLP-1 Dashboard to tackle rising therapy costs

Pharmacy benefits industry analytics provider Xevant has launched GLP-1 Dashboard, a data-driven insights solution designed to help PBMs and consultants manage the rising costs associated with GLP-1 therapies.

“Xevant’s GLP-1 Dashboard delivers a comprehensive view into plan-paid costs, utilization metrics, and member trends. By breaking down plan costs per prescription, identifying top drugs by spend, and providing cost metrics by channel, it empowers pharmacy benefits stakeholders to make data-driven decisions,” Brandon Newman, Xevant’s CEO, told Access Insider.

GPL-1 therapies, widely used to treat type 2 diabetes and obesity, have seen soaring costs over the years driven by a surge in demand. In return, placing pressure under PMBs and others to manage these expenses efficiently as well as maintaining quality care for patients, according to Xevant.

“Rising GLP-1 therapy costs have placed increasing financial pressure on employers, health plans and PBMs, driving up overall spending and necessitating new strategies to manage costs effectively,” Newman said.

“As the demand for these therapies grows, it has become critical pharmacy benefit stakeholders to understand cost trends, utilization shifts, and their implications on budgets and member affordability.”

Between 2020 and 2024, Xevant’s data revealed that costs for GLP-1 therapies for their clients increased by 1,119%, outpacing drug spending overall, which grew by 90% during the same period, the company noted.

“This insight enables more precise cost management, optimization of formulary strategies, and identification of savings opportunities within this high-cost therapeutic category,” Newman said.

Key highlights of the GLP-1 Dashboard include:

• Trend analysis of patient counts, prescription trends, adherence patterns
• Monitor and manage GLP-1 costs with monthly spend data
• Insights into prescribing habits, patient demographics and behaviors

“Unlike other solutions, Xevant's GLP-1 Dashboard offers a highly detailed, real-time view of cost metrics, utilization trends, and channel-specific data. The user-friendly interface and filtering capabilities make it easy for users to drill down into the data, providing actionable insights at a granular level,” Newman added.

“The dashboard’s focus on GLP-1 costs, along with clear data visualizations, allows for effective cost control and strategy development unmatched by other analytics solutions. We also included demographic data and the ability to compare different GLP-1 drugs to one another, enhancing targeted analysis and strategic decision-making.”

Additionally, Xevant recently launched its new AI-powered platform in November aimed to streamline healthcare data ingestion and standardization for PBMs, health plans, consultants, and employers.

Unsplash/Markus Winkler